Aptose Biosciences Inc. financial data

Symbol
APTO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
66 Wellington Street West, Suite 5300, Td Bank Tower Box 48, Toronto, Ontario, Canada
State of incorporation
Ontario, Canada
Fiscal year end
December 31
Former names
Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) (to 11/26/2014), LORUS THERAPEUTICS INC (to 9/2/2014), IMUTEC PHARMA INC (to 3/24/1998)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 88.4 % -67.2%
Debt-to-equity -439 % -813%
Return On Equity 1.02K %
Return On Assets -300 % -110%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19.5M shares +150%
Common Stock, Shares, Outstanding 19.5M shares +159%
Entity Public Float 29.6M USD -56.7%
Common Stock, Value, Issued 452M USD +1.88%
Weighted Average Number of Shares Outstanding, Basic 18.6M shares +186%
Weighted Average Number of Shares Outstanding, Diluted 18.6M shares +186%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 21.2M USD -31.4%
General and Administrative Expense 11.5M USD -28.9%
Nonoperating Income (Expense) 397K USD -71.2%
Net Income (Loss) Attributable to Parent -35.8M USD +27.3%
Earnings Per Share, Basic -3.1 USD/shares +60.9%
Earnings Per Share, Diluted -3.1 USD/shares +60.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.96M USD -49.4%
Cash, Cash Equivalents, and Short-term Investments 8M USD -54.8%
Other Assets, Current 1.36M USD +421%
Assets, Current 10.2M USD -48%
Property, Plant and Equipment, Net 30K USD -82.4%
Operating Lease, Right-of-Use Asset 664K USD -35.8%
Assets 10.9M USD -47.6%
Accounts Payable, Current 1.83M USD -34.9%
Employee-related Liabilities, Current 876K USD -56.6%
Accrued Liabilities, Current 7.51M USD -17.7%
Liabilities, Current 9.76M USD -21.2%
Operating Lease, Liability, Noncurrent 305K USD -57.6%
Liabilities 20.1M USD +53.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.32M USD -0.02%
Retained Earnings (Accumulated Deficit) -539M USD -7.11%
Stockholders' Equity Attributable to Parent -9.13M USD -217%
Liabilities and Equity 10.9M USD -47.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -37.2M USD +15.5%
Net Cash Provided by (Used in) Financing Activities 27.5M USD +350%
Net Cash Provided by (Used in) Investing Activities 1.95M USD -92.4%
Common Stock, Shares, Issued 19.5M shares +159%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.76M USD +36.8%
Deferred Tax Assets, Valuation Allowance 91.3M USD +16.7%
Deferred Tax Assets, Gross 91.3M USD +16.7%
Operating Lease, Liability 721K USD -35%
Payments to Acquire Property, Plant, and Equipment 29K USD +20.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -35.8M USD +27.3%
Lessee, Operating Lease, Liability, to be Paid 772K USD -37.4%
Property, Plant and Equipment, Gross 801K USD -14.9%
Operating Lease, Liability, Current 416K USD +6.67%
Lessee, Operating Lease, Liability, to be Paid, Year Two 197K USD -57.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 462K USD +0.65%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 198K USD
Deferred Tax Assets, Operating Loss Carryforwards 73.6M USD +22.4%
Operating Lease, Payments 461K USD +8.47%
Additional Paid in Capital 82.3M USD +14.7%
Depreciation, Depletion and Amortization 46K USD -53.1%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.41M USD -65.5%